Rapid Antidepressant Response with Ketamine: Is it the Solution to Resistant Depression?

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Treatment-resistant depression (TRD) presents a significant clinical challenge, necessitating novel pharmacological interventions.
• There is a critical need for treatments that offer both rapid and sustained antidepressant effects for TRD.
• Ketamine is known to induce a rapid antidepressant response.

Purpose of the Study:

• To evaluate the effectiveness and sustainability of ketamine's antidepressant effects in Indian subjects with TRD.
• To address the limited existing research on ketamine for TRD in India.

Main Methods:

• A 4-week, open-label, single-arm pilot study involving 22 TRD patients.
• Intravenous ketamine hydrochloride (0.5 mg/kg) administered as a single infusion after a 2-week drug-free period.
• Hamilton Depression Rating Scale (HDRS) used for outcome assessment at multiple time points pre- and post-infusion.

Main Results:

• Ketamine infusion significantly reduced HDRS scores from 80 minutes up to 3 days post-infusion.
• The antidepressant effects were statistically significant at multiple time points within the first three days.
• No significant antidepressant effect was observed after day 3 post-infusion.

Conclusions:

• Ketamine demonstrates a rapid onset of antidepressant action in TRD.
• The antidepressant effects of ketamine in this study were transient, lasting up to three days.
• Further research is needed to explore strategies for prolonging ketamine's therapeutic benefits in TRD.